Atlantic Health System

Running trials

• Recruiting

  Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer

  NCT07392892· Phase 2/3· Pfizer· Source

• Recruiting

  A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

  NCT06997497· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer

  NCT06995677· Phase 2· Tyra Biosciences, Inc· Source

• Active, not recruiting

  Siegel™ Transcatheter Aortic Valve Replacement System (TAVR) Early Feasibility Study

  NCT06680427· MiRus· Source

• Recruiting

  A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease

  NCT06100289· Phase 3· Takeda· Source

• Active, not recruiting

  A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

  NCT06388733· Phase 3· Ivy Brain Tumor Center· Source

• Recruiting

  Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

  NCT06445062· Phase 1/2· Revolution Medicines, Inc.· Source

• Recruiting

  ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves

  NCT05172973· Edwards Lifesciences· Source

• Active, not recruiting

  A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

  NCT05933577· Phase 3· Merck Sharp & Dohme LLC· Source

• Active, not recruiting

  A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM

  NCT03862430· Phase 2· NuvOx LLC· Source

• Recruiting

  Pancreatic Cancer Detection Consortium

  NCT06388967· City of Hope Medical Center· Source

• Active, not recruiting

  Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

  NCT05651022· Phase 1/2· Indaptus Therapeutics, Inc· Source

• Active, not recruiting

  SC Versus IV Isatuximab in Combination With Pomalidomide and Dexamethasone in RRMM

  NCT05405166· Phase 3· Sanofi· Source

• Recruiting

  ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

  NCT05172960· Edwards Lifesciences· Source

• Active, not recruiting

  A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

  NCT05243550· Phase 3· UroGen Pharma Ltd.· Source

• Active, not recruiting

  Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer

  NCT03539536· Phase 2· AbbVie· Source

• Recruiting

  Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)

  NCT04174157· Novartis Pharmaceuticals· Source

• Recruiting

  Pompe Disease Registry Protocol

  NCT00231400· Genzyme, a Sanofi Company· Source

• Recruiting

  Fabry Disease Registry & Pregnancy Sub-registry

  NCT00196742· Genzyme, a Sanofi Company· Source

• Recruiting

  International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

  NCT00358943· Genzyme, a Sanofi Company· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Aortic stenosis2 recruiting
• Colorectal cancer2 recruiting
• Pancreatic cancer2 recruiting
• Bladder cancer1 recruiting
• Fabry disease1 recruiting
• Gastric and oesophageal cancer1 recruiting
• Gaucher disease1 recruiting
• Pompe disease1 recruiting
• Spinal muscular atrophy1 recruiting

Closed trials

• Completed

  A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).

  NCT05578872· Phase 1/2· Anaveon AG· Source

• Completed

  In-Home Study With MiniMed™ 780G Pump Automated Control in Type 2-Evaluation of the AHCL System in Adults With Insulin-requiring Type 2 Diabetes

  NCT05238142· Medtronic MiniMed, Inc.· Source

• Recruiting

  A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

  NCT05139017· Phase 2/3· Merck Sharp & Dohme LLC· Source

• Completed

  A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.

  NCT05230186· TScan Therapeutics, Inc.· Source

• Completed

  A Study of DF6002 Alone and in Combination With Nivolumab

  NCT04423029· Phase 1· Dragonfly Therapeutics· Source

• Terminated

  Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

  NCT04203160· Phase 1/2· University of Michigan Rogel Cancer Center· Source

• Completed

  Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

  NCT04121676· Phase 1· Agenus Inc.· Source

• Completed

  A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

  NCT03872947· Phase 1· Toray Industries, Inc· Source

• Completed

  Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

  NCT03820986· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

  NCT03734016· Phase 3· BeiGene· Source

• Completed

  CardiAMP™ Cell Therapy for Heart Failure Trial

  NCT02438306· Phase 3· BioCardia, Inc.· Source

• Completed

  Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma

  NCT02360579· Phase 2· Iovance Biotherapeutics, Inc.· Source